Biogen Therapeutics’ Sale of Samsung Bioepis' to Samsung Biologics

Lee & Ko advised Biogen Therapeutics Inc. (“Biogen”) on its sale to Samsung BioLogics Co., Ltd. (“SBL”) of all the issued and outstanding shares of Samsung Bioepis Co., Ltd. (“SBE”) held by Biogen, being 50% less a share of SBE’s entire capital stock (the “Transaction”).  Lee & Ko has advised Biogen from the genesis of its joint venture with SBL, which goes back to 2012 when their joint venture agreement was first signed, through the incorporation and many capital increases of SBE as well as other governance matters, the exercise of a call option by Biogen in 2018 to increase its stake in SBE, to the Transaction at hand. Biogen has expressed its sincere satisfaction and appreciation for Lee & Ko’s prompt, steadfast and excellent counsel through the years, including on the recently executed share purchase agreement for the Transaction.